TY - JOUR
T1 - Antibody and T-Cell Responses against SARS-CoV-2 after Booster Vaccination in Patients on Dialysis
T2 - A Prospective Observational Study
AU - Kawashima, Moe
AU - Saito, Hiroaki
AU - Nishiuchi, Takamitsu
AU - Yoshimura, Hiroki
AU - Wakui, Masatoshi
AU - Tani, Yuta
AU - Nishikawa, Yoshitaka
AU - Omata, Fumiya
AU - Takita, Morihito
AU - Zhao, Tianchen
AU - Yamamoto, Chika
AU - Kobashi, Yurie
AU - Kawamura, Takeshi
AU - Sugiyama, Akira
AU - Nakayama, Aya
AU - Kaneko, Yudai
AU - Sawano, Toyoaki
AU - Shibuya, Kenji
AU - Kazama, Junichiro
AU - Shineha, Ryuzaburo
AU - Tsubokura, Masaharu
N1 - Funding Information:
This study was supported by the Japan Agency for Medical Research and Development (No. 21nf0101638). This study was also supported by Medical & Biological Laboratories Co., Ltd., Shenzhen YHLO Biotech Co., Ltd., as well as the the distributor and manufacturer of the antibody measurement system (iFlash 3000).
Funding Information:
Masaharu Tsubokura and Yurie Kobashi received a research grant from the Pfizer Health Research Foundation outside the submitted work. The authors have no conflicts of interest to declare. Yudai Kaneko belongs to MBL (Medical & Biological Laboratories Co.), the company that imported testing material used in this research. Kaneko engaged in the testing process, but was not involved in the research design or analysis.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/2
Y1 - 2023/2
N2 - Intensive vaccination is recommended for populations more vulnerable to COVID-19 infection, although data regarding the built of immunity after vaccination for dialysis patients are lacking. This prospective, observational cohort study of maintenance hemodialysis patients examined IgG antibody levels against the SARS-CoV-2 spike (S1) protein, neutralizing activity, and interferon gamma levels after the third dose of the BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine. Humoral immunity was repeatedly measured for up to two months. The study includes 58 patients on hemodialysis. Median neutralizing antibodies reached a maximum at 56 and 9 days after booster vaccination with BNT162b2 and mRNA-1273, respectively. The median IgG antibody titer reached a maximum of 3104.38 and 7209.13 AU/mL after 16 days of booster dose, and cellular immunity was positive in 61.9% and 100% of patients with BNT162b2 and mRNA-1273 vaccination, respectively. By repeating the measurements over a period of two months, we clarified the chronological aspects of the acquisition of humoral immunity in dialysis patients after a booster COVID-19 vaccination; most dialysis patients acquired not only humoral immunity, but also cellular immunity against SARS-CoV-2. Future research should investigate the continued long-term dynamics of antibody titers and cellular immunity after the third or further vaccinations, evaluating the need for additional vaccinations for hemodialysis patients.
AB - Intensive vaccination is recommended for populations more vulnerable to COVID-19 infection, although data regarding the built of immunity after vaccination for dialysis patients are lacking. This prospective, observational cohort study of maintenance hemodialysis patients examined IgG antibody levels against the SARS-CoV-2 spike (S1) protein, neutralizing activity, and interferon gamma levels after the third dose of the BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine. Humoral immunity was repeatedly measured for up to two months. The study includes 58 patients on hemodialysis. Median neutralizing antibodies reached a maximum at 56 and 9 days after booster vaccination with BNT162b2 and mRNA-1273, respectively. The median IgG antibody titer reached a maximum of 3104.38 and 7209.13 AU/mL after 16 days of booster dose, and cellular immunity was positive in 61.9% and 100% of patients with BNT162b2 and mRNA-1273 vaccination, respectively. By repeating the measurements over a period of two months, we clarified the chronological aspects of the acquisition of humoral immunity in dialysis patients after a booster COVID-19 vaccination; most dialysis patients acquired not only humoral immunity, but also cellular immunity against SARS-CoV-2. Future research should investigate the continued long-term dynamics of antibody titers and cellular immunity after the third or further vaccinations, evaluating the need for additional vaccinations for hemodialysis patients.
KW - COVID-19 vaccines
KW - cellular immunity
KW - humoral immunity
KW - renal dialysis
UR - http://www.scopus.com/inward/record.url?scp=85149204180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149204180&partnerID=8YFLogxK
U2 - 10.3390/vaccines11020260
DO - 10.3390/vaccines11020260
M3 - Article
AN - SCOPUS:85149204180
SN - 2076-393X
VL - 11
JO - Vaccines
JF - Vaccines
IS - 2
M1 - 260
ER -
